Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

Significant Accounting Policies and Basis of Presentation - Schedule of Diluted Net Loss Per Share Antidilutive (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2025	Dec. 31, 2024	Dec. 31, 2023
Schedule of Diluted Net Loss Per Share Antidilutive [Line Items]
Total	10,533,664	5,889	6,842
Warrants [Member]
Schedule of Diluted Net Loss Per Share Antidilutive [Line Items]
Total	9,834,074	1,142	384
Convertible notes payable [Member]
Schedule of Diluted Net Loss Per Share Antidilutive [Line Items]
Total	507,529
Stock Options [Member]
Schedule of Diluted Net Loss Per Share Antidilutive [Line Items]
Total	192,061	4,747